Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries
暂无分享,去创建一个
[1] G Ardine de Wit,et al. Dutch Tariff for the Five-Level Version of EQ-5D. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[2] G. Bonsel,et al. Health systems' responsiveness and reporting behaviour: Multilevel analysis of the influence of individual-level factors in 64 countries. , 2015, Social science & medicine.
[3] G. Cesana,et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases , 2013, Quality of Life Research.
[4] Zia Sadique,et al. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] Nan Luo,et al. Estimating an EQ-5D-5L Value Set for China. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[6] Nan Luo,et al. The EQ-5D-5L valuation study in Korea , 2016, Quality of Life Research.
[7] P. Kind,et al. A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[8] Paul Kind,et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] Mark Oppe,et al. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] E. van Doorslaer,et al. Cut-Point Shift and Index Shift in Self-Reported Health , 2004, Journal of health economics.
[11] R. Brooks,et al. The EuroQol Group after 25 years , 2012, Springer Netherlands.
[12] Jeffrey A. Johnson,et al. Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States , 2009, Medical care.
[13] Michael Herdman,et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D , 2010, Quality of Life Research.
[14] Nigel Rice,et al. Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness , 2011, The European Journal of Health Economics.
[15] A. Pickard,et al. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients , 2014, Quality of Life Research.
[16] R. Hays,et al. Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. , 1997, Journal of clinical epidemiology.
[17] C. Gudex,et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.
[18] P. Allen,et al. Lognormal Distributions , 1945, Nature.
[19] N. Luo,et al. Chinese time trade-off values for EQ-5D health states. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[21] J. Richardson,et al. Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and ‘micro-utility’ effects , 2015, Quality of Life Research.
[22] D. Marshall,et al. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement , 2015, Quality of Life Research.
[23] C. Terwee,et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. , 2010, Journal of clinical epidemiology.
[24] C. Pantin. Problems of Relative Growth , 1932, Nature.
[25] G. Bonsel,et al. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. , 1999, Journal of clinical epidemiology.
[26] J Hilden. Prevalence-free utility-respecting summary indices of diagnostic power do not exist. , 2000, Statistics in medicine.
[27] Brendan Mulhern,et al. Valuing health‐related quality of life: An EQ‐5D‐5L value set for England , 2017, Health economics.
[28] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[29] Mark Oppe,et al. EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes , 2016, PharmacoEconomics.
[30] Aki Tsuchiya,et al. Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies , 2012, PloS one.
[31] J. Brazier,et al. Effect of Adding a Sleep Dimension to the EQ-5D Descriptive System , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] Mark Oppe,et al. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[33] N. Devlin,et al. EQ-5D and the EuroQol Group: Past, Present and Future , 2017, Applied Health Economics and Health Policy.
[34] John Cairns,et al. In search of a common currency: A comparison of seven EQ‐5D‐5L value sets , 2018, Health economics.
[35] K. Perampaladas,et al. Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist , 2013 .
[36] Takashi Fukuda,et al. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[37] J. Hilden. The Area under the ROC Curve and Its Competitors , 1991, Medical decision making : an international journal of the Society for Medical Decision Making.
[38] D. Fairclough. Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.
[39] M. Thavorncharoensap,et al. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients , 2015, Health and Quality of Life Outcomes.
[40] J Alonso,et al. BMC Medical Research Methodology BioMed Central Study protocol Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments , 2006 .
[41] D. Fairclough. Design and Analysis of Quality of Life Studies in Clinical Trials, Second Edition , 2010 .
[42] David Parkin,et al. What Determines the Shape of an EQ-5D Index Distribution? , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[43] Jing-jing Lv,et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B , 2014, Quality of Life Research.
[44] N. Ikegami,et al. Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.
[45] Mark Oppe,et al. Comparison of the underlying constructs of the EQ-5D and Oxford Hip Score: implications for mapping. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[46] Mark Oppe,et al. Quality Control Process for EQ-5D-5L Valuation Studies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[47] Gouke J. Bonsel,et al. Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices , 2007, Quality of Life Research.
[48] Yulia Blomstedt,et al. Use of anchoring vignettes to evaluate health reporting behavior amongst adults aged 50 years and above in Africa and Asia – testing assumptions , 2013, Global health action.
[49] P. Stalmeier,et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. , 2006, Health economics.
[50] N. Bansback,et al. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada , 2015, Medical care.
[51] Markus Lahtinen,et al. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population , 2014, Health and Quality of Life Outcomes.
[52] Nan Luo,et al. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients , 2015, Quality of Life Research.
[53] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[54] G. Bonsel,et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study , 2010, Quality of Life Research.
[55] J. Brazier,et al. An Exploratory Study to Test the Impact on Three “Bolt-On” Items to the EQ-5D , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[56] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[57] T. Kohlmann,et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[58] Kevin A. Rader,et al. The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty , 2015, Clinical orthopaedics and related research.
[59] K. Boye,et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.